Sickle Cell Disease in Children: Pediatric Diagnosis and Management
Newborn screening through adolescence — penicillin prophylaxis, hydroxyurea initiation, transcranial Doppler stroke screening, vaso-occlusive crisis treatment, splenic sequestration recognition, acute chest syndrome, and emerging disease-modifying therapies including crizanlizumab and gene therapy.
Executive Summary
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a single nucleotide substitution (β6 Glu→Val) producing hemoglobin S. Universal newborn screening detects approximately 1 in 365 African American births in the US. Penicillin prophylaxis 125 mg PO BID (<3 yrs), 250 mg PO BID (3–5 yrs) beginning by 2 months reduces pneumococcal mortality by 84% and is continued through age 5. Hydroxyurea starting 20 mg/kg/day, titrated to 35 mg/kg/day is recommended for ALL children with HbSS or HbSβ⁰ thalassemia beginning at 9 months regardless of clinical severity. Annual transcranial Doppler (TCD) screening from age 2–16 identifies high-stroke-risk children (TAMV ≥200 cm/s) who benefit from chronic transfusion programs (NEJM STOP trial: 92% stroke reduction). Acute chest syndrome and splenic sequestration are leading causes of pediatric mortality and require immediate hospitalization. Disease-modifying agents now include crizanlizumab (P-selectin antibody), L-glutamine, and curative options: matched sibling HSCT (85–95% event-free survival) and FDA-approved gene therapies (exa-cel, lovo-cel, December 2023).
Pathophysiology and Genetics
Sickle cell disease results from a single nucleotide substitution (GAG→GTG) in the β-globin gene at codon 6, replacing glutamic acid with valine to produce hemoglobin S (HbS). When deoxygenated, HbS molecules polymerize into long fibers that distort red blood cells into rigid, sickle-shaped erythrocytes with reduced deformability and a half-life of 10–20 days (vs 120 days for normal RBCs). The clinical phenotype reflects two pathophysiologic processes: chronic hemolytic anemia and recurrent vaso-occlusion driven by adhesion of sickled cells, neutrophils, and platelets to activated endothelium.
Common Genotypes
| Genotype | Designation | Severity | Hb Range |
|---|---|---|---|
| HbSS (homozygous) | Sickle cell anemia | Severe — most complications | 6–9 g/dL |
| HbSβ⁰ thalassemia | Sickle β⁰ | Severe (similar to SS) | 6–9 g/dL |
| HbSC disease | Compound heterozygous | Moderate — fewer crises, more retinopathy/AVN | 10–13 g/dL |
| HbSβ⁺ thalassemia | Sickle β⁺ | Mild-moderate (depends on β⁺ mutation) | 9–12 g/dL |
| HbAS | Sickle cell trait (carrier) | Asymptomatic; rare exertional rhabdomyolysis | Normal |
Why Symptoms Begin After 6 Months
At birth, fetal hemoglobin (HbF, α₂γ₂) constitutes 60–80% of total hemoglobin and protects against polymerization (γ-globin lacks the β6 residue). HbF declines from approximately 80% at birth to <2% by 12 months as adult hemoglobin (HbA, α₂β₂) — or in SCD, HbS — replaces it. Clinical manifestations therefore emerge between 4–6 months: dactylitis (hand-foot syndrome), splenic sequestration, anemia. This window underlies the urgency of newborn screening — to start preventive care before symptoms.
Splenic Involution Timeline
Repeated splenic infarction in early childhood causes functional asplenia by approximately 1–2 years (HbSS) or later (HbSC). By age 5, anatomic autosplenectomy is typical. This timeline drives the rationale for early penicillin prophylaxis: encapsulated organism (especially Streptococcus pneumoniae) sepsis carries 30–35% mortality in unprotected SCD children.
Newborn Screening and Diagnosis
Universal newborn screening for SCD is mandatory in all 50 US states. Heel-prick blood spots are analyzed by isoelectric focusing (IEF), high-performance liquid chromatography (HPLC), or capillary electrophoresis. Result patterns:
| Pattern | Interpretation | Confirmation |
|---|---|---|
| FA | Normal (HbF + HbA) | None needed |
| FAS | Sickle cell trait (HbAS) | Repeat at >6 months for confirmation |
| FS | HbSS or HbSβ⁰ thalassemia | Family studies + DNA sequencing for βᶬᵃˡⁿ thalassemia variants |
| FSC | HbSC disease | HPLC confirms; counsel parents |
| FSA | HbSβ⁺ thalassemia (not trait) | Family studies, β-globin gene sequencing |
| F only | β-thalassemia major possibility OR delayed sample | Repeat HPLC at 2 months |
Why “F” Comes First in NBS Notation
Hemoglobins are reported in order of abundance. At birth HbF predominates (60–80%), so “FA” indicates normal newborn (HbF more than HbA). “FS” without A indicates that HbA is absent — diagnostic of HbSS or HbSβ⁰ (the latter has no β-globin to make HbA). HbA appearance by 6 months distinguishes HbSβ⁺ from HbSβ⁰.
Confirmatory Testing
- Repeat HPLC at 2 months: confirms initial NBS finding
- Parental hemoglobin electrophoresis: confirms inheritance pattern, identifies β-thalassemia minor
- β-globin gene sequencing: when phenotype-genotype mismatch, atypical patterns, or for prenatal counseling for future pregnancies
- α-globin gene analysis: if microcytosis disproportionate to anemia (concomitant α-thalassemia softens phenotype)
Diagnostic Confirmation Pathway Beyond Newborn Screen
The newborn screening (HPLC or isoelectric focusing) flags an FS pattern but is not sufficient for definitive diagnosis or genotype clarification — confirmation testing must follow within 3–6 months. The standard workflow: repeat hemoglobin electrophoresis (HPLC or IEF) at 3–6 months of age to confirm FS (sickle cell anemia, HbSS), FSC (HbSC disease), FSA (sickle-beta-thalassemia with persistent fetal hemoglobin in infancy), or FAS (sickle trait, not disease). Genotype confirmation by DNA sequencing of the beta-globin gene (HBB) for definitive classification, particularly to distinguish HbS-beta-zero thalassemia (severe phenotype like HbSS) from HbS-beta-plus thalassemia (milder); these have very different long-term outcomes and screening intensities. Family studies when parental genotypes are unknown — both parents tested with electrophoresis to confirm trait or disease status, with genetic counseling for future pregnancies. Baseline labs include CBC with reticulocyte count, ferritin, LDH, bilirubin, BUN/creatinine, and urinalysis to establish baseline values that will be tracked across childhood. The diagnostic confirmation visit at 3–6 months is also when penicillin prophylaxis is initiated, hydroxyurea conversation begins for age 9 months start, and the comprehensive sickle cell center referral is made if not done at newborn screening. Without this confirmation visit, families are sometimes managed for months on the wrong assumption (HbSS vs HbSC vs HbS-beta-thal) with very different surveillance schedules.
Preventive Care and Health Maintenance
Comprehensive preventive care has transformed pediatric SCD outcomes — childhood mortality declined from 25–30% (pre-1980) to <5% in the modern era largely through penicillin prophylaxis, conjugate vaccines, TCD screening, and hydroxyurea.
Penicillin Prophylaxis
| Age | Penicillin V Dose | Penicillin-Allergic Alternative |
|---|---|---|
| Birth – 3 months | Begin by 2 months: 125 mg PO BID | Erythromycin 10 mg/kg PO BID |
| 3 months – 3 years | 125 mg PO BID | Erythromycin 125 mg PO BID |
| 3 – 5 years | 250 mg PO BID | Erythromycin 250 mg PO BID |
| ≥5 years (HbSS only) | Discontinue if no prior pneumococcal sepsis AND fully vaccinated AND splenectomy not performed | Continue if splenectomized OR prior IPD |
Vaccinations (in addition to routine schedule)
| Vaccine | Schedule | Rationale |
|---|---|---|
| PCV13/PCV15/PCV20 (pneumococcal conjugate) | Routine ages 2, 4, 6, 12–15 months | Functional asplenia |
| PPSV23 (pneumococcal polysaccharide) | Age 2 years (≥8 wk after last PCV), repeat at age 7 years | Broader serotype coverage |
| Meningococcal ACWY conjugate | Series starting age 2 months (4 doses), boosters every 5 years | Asplenia risk for meningococcal sepsis |
| Meningococcal B (Bexsero/Trumenba) | Begin at 10 years | Functional asplenia |
| Annual influenza vaccine | Beginning at 6 months | Influenza precipitates ACS and VOC |
Transcranial Doppler (TCD) Screening
The STOP and STOP II trials established that annual TCD ultrasonography in children with HbSS or HbSβ⁰ from age 2–16 identifies those at high stroke risk who benefit from chronic transfusion. Time-averaged maximum mean velocity (TAMV) of the middle cerebral artery is the key parameter:
| TAMV (cm/s) | Risk Category | Action |
|---|---|---|
| <170 | Normal | Repeat annually |
| 170–199 | Conditional | Repeat in 1–3 months |
| ≥200 (or inadequate study) | Abnormal — high stroke risk (~10%/year without intervention) | Confirm within 2–4 weeks; initiate chronic transfusion (target HbS <30%) |
Other Preventive Measures
- Folic acid: 1 mg PO daily from infancy (chronic hemolysis demands)
- Annual ophthalmologic exam: begin at age 10 (HbSC: starting age 5–8 due to higher proliferative retinopathy risk)
- Annual urine albumin/creatinine: begin at age 10 to detect SCD nephropathy
- Pulse oximetry at every visit: baseline SpO₂ <95% predicts ACS risk and pulmonary hypertension
- Audiology screening: baseline at age 5 (sensorineural hearing loss in 12% of SCD children)
- Echocardiogram: baseline at age 8–10 to screen for tricuspid regurgitant jet velocity (TRV) ≥2.5 m/s suggesting pulmonary hypertension
Acute Complications and Management
Vaso-Occlusive Crisis (VOC)
Severe acute pain from microvascular occlusion typically affecting bones (extremities, back, chest, abdomen). Triggers: dehydration, infection, cold exposure, stress, hypoxia, acidosis. Management priorities: aggressive analgesia, hydration, oxygen if hypoxic, infection screen.
| Pain Severity | First-Line | Second-Line / Severe |
|---|---|---|
| Mild (NRS 1–3) | Acetaminophen 15 mg/kg PO q6h (max 75 mg/kg/day) + ibuprofen 10 mg/kg PO q6h | Heat, hydration; home-based |
| Moderate (NRS 4–6) | Add oxycodone 0.1–0.2 mg/kg PO q4h to acetaminophen/ibuprofen | ED if no relief in 1 hour |
| Severe (NRS 7–10) | Morphine 0.1–0.15 mg/kg IV q3–4h OR hydromorphone 0.015 mg/kg IV q3–4h; first dose within 30 min of arrival | PCA (patient-controlled analgesia); ketorolac 0.5 mg/kg IV q6h × 5 days max |
Avoid Meperidine (Demerol)
Meperidine is contraindicated in SCD due to normeperidine accumulation causing seizures, especially with renal involvement. Avoid codeine in children <12 years (FDA black box for ultra-rapid metabolizers). Tramadol carries similar concerns. Morphine and hydromorphone are preferred opioids.
Acute Chest Syndrome (ACS)
New pulmonary infiltrate on chest X-ray PLUS one of: fever, chest pain, tachypnea, hypoxia, cough, wheezing. Mortality 1–3% in children, leading cause of pediatric SCD death after age 1. Etiologies: infection (40%, atypicals + RSV common), fat embolism from bone marrow infarction, hypoventilation from chest wall pain, in situ pulmonary microvascular sickling.
ACS Management Bundle
- Empiric antibiotics: ceftriaxone 75 mg/kg IV daily (max 2 g) + azithromycin 10 mg/kg PO/IV daily × 5 days
- Oxygen to maintain SpO₂ ≥95%
- Incentive spirometry every 1–2 hours awake (10 maximal inhalations)
- Adequate analgesia (allows deeper breathing) but avoid over-sedation
- Bronchodilators if wheezing or reactive airways
- Maintenance IV fluids at 0.75–1× maintenance only (avoid pulmonary edema)
- Simple transfusion if Hb >1 g/dL below baseline + hypoxia
- Exchange transfusion (target HbS <30%) if: rapid clinical deterioration, multilobar infiltrates, FiO₂ >40% requirement, prior ACS
Splenic Sequestration
Sudden trapping of large blood volume in spleen — more common ages 6 months to 3 years (HbSS) or any age (HbSC). Presents with rapid Hb drop ≥2 g/dL, splenomegaly (often dramatically enlarged), reticulocytosis, hypovolemic shock. Mortality 12% per episode if untreated. Recurrence rate 50% — splenectomy after second episode.
Parent Education — Spleen Palpation
Teach parents to palpate the child’s spleen daily during well periods so they can detect sudden enlargement. Hospitalize immediately for any acute splenic enlargement with pallor, lethargy, or tachycardia. Transfuse cautiously — release of sequestered blood after transfusion can cause volume overload (target Hb 8 g/dL, not normal).
Stroke
Overt stroke incidence 11% by age 20 in untreated HbSS. Acute management: emergent MRI/MRA brain (CT first if MRI unavailable), neurology consultation, exchange transfusion to HbS <30% (don’t wait for diagnostic confirmation if high suspicion), control fever/hypoxia. Initiate chronic transfusion program — discontinuation triples recurrent stroke risk.
Other Acute Presentations
| Complication | Recognition | Management |
|---|---|---|
| Aplastic crisis (parvovirus B19) | Acute Hb drop with reticulocytopenia (<1%) | Transfusion if symptomatic; isolation (parvo highly contagious to pregnant staff) |
| Priapism | Painful erection >4 hours | Hydration, analgesia, urology consult; aspiration + irrigation if >4h; pseudoephedrine for stuttering priapism prophylaxis |
| Dactylitis (hand-foot syndrome) | Painful swelling of hands/feet, age 6 mo–4 yrs (often first VOC) | Acetaminophen/ibuprofen, hydration; rules out osteomyelitis if persistent |
| Sepsis (encapsulated organism) | Fever ≥38.5°C, ill appearance | Blood culture + IV ceftriaxone 75 mg/kg within 60 min — admit if <1 yr or ill; consider outpatient if vaccinated and well-appearing >1 yr per protocol |
Disease-Modifying Therapies
Hydroxyurea
The cornerstone of SCD disease modification. Mechanism: induces HbF expression (γ-globin reactivation), reduces neutrophil/reticulocyte counts, decreases adhesion molecule expression, NO donor effects. NHLBI 2014 and 2024 ASH guidelines recommend hydroxyurea for ALL children with HbSS or HbSβ⁰ thalassemia starting at 9 months of age regardless of clinical severity (BABY HUG trial demonstrated benefit in asymptomatic infants).
Hydroxyurea Dosing Protocol
| Step | Dose | Monitoring |
|---|---|---|
| Starting dose | 20 mg/kg/day PO once daily | CBC + retic q4 weeks |
| Escalation | Increase by 5 mg/kg every 8 weeks | If ANC >2.0 K, plt >80 K, retic >100 K |
| Maximum tolerated dose (MTD) | Up to 35 mg/kg/day | Goal: HbF ≥20%, MCV ↑, mild marrow suppression |
| Toxicity (hold and reduce) | — | ANC <1.0 K, plt <80 K, retic <80 K, Hb drop >20% from baseline |
Counsel families: not chemotherapy in this dose range, no proven adverse effect on growth or fertility, but contraception in adolescents (theoretical teratogenicity). Take with food to reduce GI upset.
Newer Disease-Modifying Agents
| Agent | Mechanism | Indication / Dose | Notes |
|---|---|---|---|
| Crizanlizumab (Adakveo) | P-selectin monoclonal antibody — blocks adhesion | Age ≥16 yrs: 5 mg/kg IV at 0, 2 weeks, then q4 weeks | SUSTAIN trial: 45% reduction in VOC frequency |
| L-glutamine (Endari) | Antioxidant — replenishes intracellular NAD redox balance | Age ≥5 yrs: 0.3 g/kg PO BID (max 30 g/day) | 25% reduction in VOC; powder formulation |
Voxelotor (Oxbryta) was withdrawn from all markets worldwide by its manufacturer in September 2024.
Curative Options
Hematopoietic Stem Cell Transplantation (HSCT)
Matched sibling donor (MSD) HSCT offers cure with 95% overall survival and 85–90% event-free survival in children. Indications: stroke, abnormal TCD on transfusion, recurrent ACS, recurrent severe VOC despite hydroxyurea, end-organ damage. Conditioning: myeloablative (busulfan + cyclophosphamide ± ATG) for younger children; reduced-intensity for older. Limitations: only ~15% of patients have matched sibling; haploidentical and matched unrelated donor protocols (ongoing trials) expanding access.
Gene Therapy (FDA-Approved December 2023)
- Exa-cel (Casgevy, Vertex/CRISPR): CRISPR/Cas9 editing of BCL11A enhancer in autologous CD34+ cells → reactivates HbF. Approved age ≥12 yrs. CLIMB-121 trial: 97% VOC-free at 24 months.
- Lovo-cel (Lyfgenia, bluebird bio): Lentiviral transduction inserting modified β-globin gene (βᴬᵀ⁸⁷ᵠ — anti-sickling). Approved age ≥12 yrs. Black box warning for hematologic malignancy (2 cases of myelodysplastic syndrome).
When to Refer to Comprehensive SCD Center
Pediatric Hematology: all newly diagnosed SCD children for comprehensive baseline assessment, hydroxyurea initiation, family education, and ongoing surveillance. HSCT/Cell therapy team: any child with stroke, abnormal TCD that fails to normalize on transfusion, recurrent ACS (≥2 episodes), severe pain frequency despite optimized hydroxyurea, or significant end-organ damage. Pediatric pulmonology: recurrent ACS, pulmonary hypertension (TRV ≥2.5 m/s on echo), sleep apnea (obstructive sleep apnea precipitates VOC). Genetic counseling: at-risk family members planning pregnancy.
✓ Pearl: Fever Is Always an Emergency
Any temperature ≥38.5°C in a child with SCD (especially <5 years) requires immediate ED evaluation, blood culture, and empiric IV ceftriaxone within 60 minutes. Pneumococcal sepsis can progress to death within hours in functionally asplenic children. Never tell a parent to “watch and wait” with a febrile SCD child.
✗ Pitfall: Avoid Iron Supplementation
SCD patients are NOT iron deficient — they have normal or increased iron stores from chronic hemolysis. Inappropriate iron supplementation worsens iron overload, especially in chronically transfused patients. Confirm iron deficiency with ferritin and transferrin saturation before supplementing. Address true iron deficiency (commonly from menorrhagia in adolescents) with appropriate dosing.
Practice Insights — Bedside Notes on Pediatric Sickle Cell Disease
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across published practice patterns, the consistent saver is starting hydroxyurea at 9 months of age as the BABY HUG trial supported, not waiting for severe complications, and annual TCD surveillance from age 2 to 16 to catch high stroke-risk velocity before the first event.
Hydroxyurea From 9 Months — Not “Wait for Severe Disease”
The BABY HUG trial in 2011 established that hydroxyurea started at 9–18 months of age in infants with HbSS disease reduces pain events, dactylitis, acute chest syndrome, and transfusion needs without significant toxicity. In practice every HbSS or HbS-beta-zero thalassemia patient gets hydroxyurea offered at the 9-month visit at starting dose 20 mg/kg/day, titrated by 5 mg/kg every 8 weeks to a maximum tolerated dose (MTD) of approximately 35 mg/kg/day, limited by neutrophil count (target ANC >2000), platelets (>80,000), or HbF response. The older paradigm of “wait until disease severity warrants it” has been replaced by universal early initiation. Some parents need multiple conversations to commit to long-term therapy, but the published outcome data are convincing enough to keep returning to the conversation.
Annual TCD From Age 2 to 16 — Primary Stroke Prevention
Transcranial Doppler ultrasound annually from age 2 to 16 in children with HbSS or HbS-beta-zero thalassemia identifies elevated middle cerebral or internal carotid artery velocities (≥200 cm/s = high risk; 170–199 cm/s = conditional risk) that predict overt stroke without intervention. The STOP and STOP2 trials established that chronic transfusion reducing HbS to less than 30% in high-velocity patients lowers stroke risk by 90%. In practice TCD is scheduled at every annual visit; high-velocity patients enter chronic transfusion programs or, increasingly, hydroxyurea-at-MTD with TCD reassessment per the TWiTCH trial framework. Skipping annual TCD is how children develop catastrophic and preventable first strokes.
Acute Chest Syndrome — Don’t Over-Hydrate
Acute chest syndrome (new infiltrate on chest imaging plus respiratory symptoms) is the leading cause of disease-related death in pediatric SCD, with mortality 5–10% in severe cases. The reflex to flood ACS patients with IV fluids worsens the condition by precipitating ARDS-like pulmonary edema. In practice ACS hospitalization gets specific fluid restriction to maintenance only (not 1.5× or 2× maintenance), supplemental oxygen targeting SpO2 ≥95% (not flush), empiric antibiotics covering S. pneumoniae plus atypicals (ceftriaxone 50 mg/kg IV daily plus azithromycin 10 mg/kg PO/IV), incentive spirometry every 1–2 hours while awake to prevent atelectasis, and exchange transfusion (simple if HbS >30%, exchange if severe or HbS >30%) for hypoxemia or expanding infiltrates. The fluid restriction is the most counterintuitive part for trainees who default to aggressive resuscitation.
Family Education on Splenic Sequestration Catches Crises Early
Acute splenic sequestration crisis can drop hemoglobin by 2–3 g/dL within hours in young children with HbSS who have not yet auto-splenectomized; mortality without prompt recognition is very high. In practice every family of an HbSS or HbS-beta-thal child gets explicit teaching on left upper quadrant splenic palpation at every clinic visit, starting at the 6-month visit. Parents demonstrate the palpation technique back to experienced clinicians before discharge. The instruction is unambiguous: any palpable spleen that is larger than the documented baseline goes to the ED immediately, not to clinic the next day, not “let’s see how it does overnight.” Cycles of parental teaching, return demonstration, and reinforcement at every visit have prevented multiple potentially fatal sequestration crises in experienced practice.
Illustrative Scenario — TCD-Detected High Velocity Triggered Transfusion Program
(Composite teaching scenario assembled from published patterns; not an individual patient.)A girl with HbSS sickle cell disease followed from newborn screen had been on hydroxyurea since age 9 months at MTD of 30 mg/kg/day with stable HbF around 20%, no overt strokes, and only minor pain events over years of follow-up. At her routine age-6 annual visit, TCD performed by the pediatric neurology lab returned right MCA mean velocity 215 cm/s and left MCA 198 cm/s — high-risk on the right, conditional on the left. Brain MRI/MRA showed no overt infarcts but evidence of small-vessel disease. After discussion with the family clinicians started chronic monthly simple transfusion targeting HbS <30% (transfusion every 3–4 weeks with iron chelation initiated when ferritin exceeded 1000 ng/mL using deferasirox). TCD at 6 months and 12 months had normalized to under 170 cm/s. The family enrolled in the TWiTCH-style transition study with goal eventually transitioning back to hydroxyurea-at-MTD once TCD normalizes durably. She remained stroke-free at 4-year follow-up.
Takeaway: hydroxyurea starting at 9 months plus annual TCD from age 2 catches the high-velocity phenotype before the stroke. Chronic transfusion with iron chelation manages stroke risk; the TWiTCH framework allows transition back to hydroxyurea if velocities normalize durably.
Protocol Adjustments Seasoned Clinicians Use Beyond the Standard Guideline
- Hydroxyurea offered at 9-month visit for all HbSS / HbS-beta-zero thal — start 20 mg/kg/day, titrate to MTD ~35 mg/kg/day. BABY HUG trial replaced “wait for severe disease” paradigm.
- Annual TCD from age 2 to 16 — MCA/ICA mean velocity ≥200 cm/s = high risk → chronic transfusion or hydroxyurea-MTD with TWiTCH-style monitoring. Skipping TCD = preventable first stroke.
- ACS management: fluid RESTRICTION + O2 to 95% + empiric ceftriaxone + azithromycin + incentive spirometry q1–2h + exchange transfusion if severe — over-resuscitation precipitates ARDS-like pulmonary edema. Maintenance fluids only.
- Splenic palpation teaching with return demonstration at every visit from 6 months — any spleen larger than baseline = immediate ED. Cycles of teaching prevent fatal sequestration crises.
FAQ and Clinical Pearls
✓ Pearl: Pediatric to Adult Transition
SCD mortality bimodally peaks at age 1–3 years (sepsis, sequestration) and again in late adolescence/early adulthood (transition gap, ACS, multiorgan failure). Begin transition planning at age 12 with structured education, gradual independence in self-care, and warm handoff to adult SCD provider by age 21. The “transition cliff” causes preventable deaths — formal transition programs reduce ED visits by 30%.
✗ Pitfall: Underdosing Hydroxyurea
Hydroxyurea is most effective at maximum tolerated dose (MTD), typically 25–35 mg/kg/day. Many providers underdose at the starting 20 mg/kg without escalating, blunting clinical benefit. Aim for marrow suppression markers: HbF ≥20%, MCV increase by ≥5 fL, mild ANC reduction (1.5–4.0 K). Do not stop hydroxyurea during illness — continued therapy reduces VOC severity.
- Pneumothorax Diagnosis and Management: A Comprehensive Clinical Guideline
- Alpha-1 Antitrypsin Deficiency: ATS/ERS Diagnosis, PiZZ Genotyping, and Augmentation Therapy in COPD and Liver Disease
- Nontuberculous Mycobacterial Lung Disease: MAC and M. abscessus Diagnosis and Treatment
- Chronic Obstructive Pulmonary Disease — Diagnosis and Stepwise Management
- Autosomal Dominant Polycystic Kidney Disease: Mayo Classification, Tolvaptan, and Long-Term Management
- Hyperkalemia: Diagnosis, Acute Management, and Novel Potassium Binders